Publications

In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster

Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-62

Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-69

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the United States from 2014 through 2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist.: in press, 2019.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). by Sader HS, Castanheira M, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis.: in press, 2019.

The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. by Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2019; 63 (7): e00355

Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin and fosfomycin against well characterized multi-drug resistant K. pneumoniae and P. aeruginosa. by Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M and Rybak MJ. Antimicrob. Agents Chemother. 2019; 63 (8): e00779

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin. by Miller A, Traczewski T, Huband M, Bradford P and Mueller J. published in J. Clin. Microbiol, 2019 57 (9): e00567

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. by Castanheira M, Doyle TB, Smith CJ, Mendes RE and Sader HS. published in J. Antimicrob. Chemother. 2019; 74 (9): 2588-2595

Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates. Lead author LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-717

Antimicrobial Activity of Ceftibuten-Clavulanate When Tested against Clinical Enterobacterales Isolates Collected Worldwide in 2017. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-718

Antimicrobial Activity of Plazomicin Tested against a Worldwide Collection of Enterobacterales Isolated from Patients with Complicated Urinary Tract Infections (2014-2017). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-591

Correlation between Broth Microdilution and Disk Diffusion Results When Testing Ceftazidime-Avibactam against a Challenge Collection of Enterobacterales: Results from a Multi-Laboratory Study. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-CPHM-866

Plazomicin is Active against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases, Carbapenemases, and Aminoglycoside-Modifying Enzymes from United States (US) Hospitals. Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-596

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-730

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centers in the United States and Latin America (2018). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-599

Activity of Meropenem-Vaborbactam and Characterization of Carbapenem Resistance Mechanisms among Carbapenem-Resistant Enterobacteriaceae from United States Hospitals (2016-2017). Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-594

Ceftibuten-Clavulanate Activity against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-780

Cefepime-Zidebactam (WCK 5222) Activity when Tested against Enterobacterales Isolated from Patients Hospitalized in the United States and Latin America in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA
# Saturday-AAR-754

In Vitro Activity of Tedizolid and Comparator Agents against Gram-Positive Isolates Causing Bloodstream Infections in US and European Hospitals (2018). Lead Author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-612

Evaluation of Tebipenem Activity Tested against a Collection of Isogenic Escherichia coli Strains Producing Various Clinically Relevant β-Lactamases. Lead author: LM Deshpande, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-778

Tedizolid In Vitro Activity against a Collection of Multidrug-Resistant Gram-Positive Clinical Isolates from US Medical Centers (2017-2018). Lead author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-611

Monitoring the In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Current Collection of Surveillance Enterobacterales Clinical Isolates (2018). Lead author: RE Mendes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-777

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-607

Activity of Investigational Polymyxin-B-Like Compound (SPR206) against Set of Gram-Negative Bacilli Responsible for Human Infections. Lead author: SJR Arends, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-796

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against US Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ASM Microbe 2019, June 20-24, San Francisco, CA USA
#Friday-AAR-538

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results. Lead author: MD Huband presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-540

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-542

In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017). by Pfaller MA, Huband MD, Flamm RK, Bien PA and Castanheira M. published in Antimicrob. Agents Chemother. 2019; 63 (8), e00840

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia. by Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD and Flamm RK. published in Open Forum Infect. Dis. 20196 (6): ofz240

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis.: in press, 2020; 96: 114833

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). by Carvalhaes CG, Sader HS, Flamm RK and Mendes RE. published in J. Antimicrob. Chemother. 2019; 74 (7): 1928-1933

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. by Huband MD, Pfaller MA, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist.: in press, 2019.

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States. by Pfaller MA, Sader HS, Rhomberg PR, Flamm RK and Mendes RE. published in Microb. Drug Resist. 2019; 25 (6), 938-943

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). by Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE and Sader HS. published in Diagn. Microbiol. Infect. Dis., 2019; 94 (3): 304-313

Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae, including a challenge set of organisms. by Arends SJR, Rhomberg PR, Cotroneo N, Rubio A, Flamm RK and Mendes RE. published in Antimicrob. Agents Chemother.: in press, 2019.

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals. by Castanheira M, Doyle TB, Mendes RE and Sader HS. published in Antimicrob. Agents Chemother. 2019; 63 (7), e00160

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). by Sader HS, Castanheira M, Arends SJR, Goossens H and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (6): 1595-1606

Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents when tested against gram-negative bacterial strains using time-kill curves. by Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ and Shortridge D. published in Antimicrob. Agents Chemother. 2019; 63 (5): e02549

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. by Carvalhaes CG, Castanheira M, Sader HS, Flamm RK and Shortridge D. Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 93-102

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. by Castanheira M, Davis AP, Serio AW, Krause KM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 73-77.

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers. By Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK. Antimicrob. Agents Chemother. 63 (6): e02655, 2019.

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2017-2018). Lead author: HS Sader, presented at ATS 2019, May 17-22, Dallas, Texas, USA
#8470

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data. Lead author: LM Deshpande, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2686

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2162

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783